A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

Inclusion Criteria: * Participants with Type 2 Diabetes (T2DM). * Participants who are insulin naive or receiving basal insulin \[NPH (neutral protamine Hagedorn) once or twice daily, once-daily insulin glargine U100 or U300, once-daily insulin degludec, or insulin detemir once or twice daily\] for fewer than 5 years prior to screening. * Have glycated hemoglobin (HbA1c) of ≥7.0 percent (%) to ≤9.5%, HbA1c of ≥6.5% to ≤9.5% for participants on treatment with sulfonylureas and/or Sodium-Glucose Transport Protein 2 inhibitors who require washout. * Have a body mass index between 27 and 40 kilograms per meter square. * Male or female participants who are willing to comply with the contraception requirements consistent with local regulations. * Be willing to allow blood sample collection, reliable and to be available for the duration of the study as required for the study protocol. Exclusion Criteria: * Have known or suspected allergic reactions to study drugs, related compounds, excipients, and devices used in the study. * Have a specific type of diabetes other than T2DM. * Have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c. * Participants with a history of kidney complications.